Methods to increase insulin secretion
Pro Research Analysisby 
Searched over 200M research papers
Pharmacological Agents to Increase Insulin Secretion
Several drugs can directly enhance insulin secretion by acting on pancreatic β-cells. Sulfonylureas, benzoic acid derivatives, imidazolines, and quinolines act primarily by modulating KATP channels, leading to cell depolarization and insulin release. Methylxanthines increase insulin secretion by antagonizing purinergic receptors at the cell membrane. Other agents, such as calcineurin inhibitors and somatostatin, affect insulin secretion at multiple cellular levels, including second-messenger pathways and cytoskeletal dynamics. Additionally, racemic ranolazine and its enantiomers have been shown to enhance endogenous insulin levels, either alone or in combination with other anti-diabetic agents12.
Dietary and Nutritional Approaches
Carnosine, a naturally occurring dipeptide, can double insulin secretion by scavenging reactive species that inhibit β-cell function. It also reverses the negative effects of glucolipotoxicity on insulin secretion, suggesting that carnosine or its analogs could be a novel therapeutic option for type 2 diabetes. Furthermore, increasing plasma non-esterified fatty acids (NEFA) through oral fat feeding, especially monounsaturated fatty acids, augments glucose-stimulated insulin secretion. This effect is partly due to increased GLP-1 levels, with monounsaturated fats having the greatest impact compared to polyunsaturated and saturated fats.
Cellular and Molecular Mechanisms
Enhancing the transfer of reducing equivalents within β-cells, specifically through cytosolic isocitrate dehydrogenase, increases NADPH and reduced glutathione levels. This activates SENP1, which amplifies insulin exocytosis. Restoring NADPH or activating SENP1 can improve insulin secretion even in β-cells from individuals with type 2 diabetes.
Extracellular Matrix and Islet Microenvironment
Encapsulating islets in hydrogels functionalized with extracellular matrix proteins, such as collagen type IV and laminin, significantly increases insulin secretion. Laminin, in particular, can boost insulin release up to six-fold compared to islets without matrix proteins. The effect is mediated by specific interactions with cell surface integrins, highlighting the importance of the islet microenvironment in supporting β-cell function.
Receptor-Mediated Pathways
G-protein coupled receptor 55 (GPR55) agonists, such as O-1602 and abnormal cannabidiol, increase insulin secretion by promoting inositol trisphosphate (IP3)-mediated calcium release from intracellular stores. This calcium mobilization is essential for the enhanced insulin response in β-cells. Thiazolidinediones (TZDs) also enhance insulin secretion via GPR40 and adenylate cyclase pathways, further supporting the role of receptor-mediated mechanisms in insulin regulation.
Incretin-Based Strategies
Glucagon-like peptide-1 (GLP-1) is a potent stimulator of insulin secretion. GLP-1 enhances glucose-stimulated insulin secretion by activating protein kinase C (PKC)-dependent TRPM4 and TRPM5 channels, leading to membrane depolarization and increased insulin release. This effect is independent of the classical PKA pathway and highlights the direct action of GLP-1 on β-cells. Additionally, increasing the number of GLP-1-producing L cells in the intestine, for example by blocking NOTCH signaling, augments GLP-1 secretion and improves insulin responses and glucose tolerance in diabetic models.
Conclusion
Multiple strategies exist to increase insulin secretion, including pharmacological agents targeting β-cell ion channels and receptors, dietary interventions, modulation of cellular redox states, enhancement of the islet microenvironment, and incretin-based therapies. Combining these approaches or developing new agents that act through novel mechanisms may offer improved outcomes for individuals with impaired insulin secretion or type 2 diabetes1234+6 MORE.
Sources and full results
Most relevant research papers on this topic